Soo-Chin Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Soo-Chin Lee has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
Hui-Ling Yap
6 shared publications- Boon Cher Goh
National University Hospital Singapore, Singapore, Singapore
4 shared publications Boon-Cher Goh
4 shared publicationsChiung-Ing Wong
4 shared publicationsRaghav Sundar
Department of Haematology-Oncology, National University Cancer Institute, National University Health System, Singapore, Singapore
3 shared publications- Ross A. Soo
National University Cancer Institute, National University Health System, Singapore, Singapore, Singapore
3 shared publications
Latest Publications
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35  (15_suppl) , 2550
Whole exome sequencing (WES) of multiple spatially distinct biopsies from single metastatic lesions to evaluate tumour heterogeneity and identify actionable truncal mutations (ATMs) in patients (pts) with advanced solid malignancies using a radiologically-guided single-pass percutaneous technique.
2550 Background: Genomic profiling of single core biopsies (bx) are confounded intratumoral heterogeneity, resulting in sampling bias. We explored the use of a novel technique to obtain multiple bx from single metastatic lesion in pts to evaluate heterogeneity and identify therapeutic ATM. Methods: 15 pts (5 NSCLC; 3 ovarian; 2 colon, 2 uterine and 1 breast, cervix and HCC) with biopsiable lesions were identified. Using a single pass radiologically guided percutaneous bx technique, we obtained multiple spatially distinct core bx samples from a single metastatic lesion. Each bx underwent DNA extraction and WES using the NextSeq500. Results: Median of 4 core bx were obtained from each lesion. Complication rate utilizing this technique was 0%. 2 pts were omitted from analysis due to poor quality DNA with 13 pts successfully sequenced. In 1 pt, only 2 of 4 cores were successfully sequenced. The median amounts of total and non-synonymous variants were 137 (27-1286) and 66 (10-649) respectively. The median (range) filtered variants detected in 1/4, 2/4, 3/4, and 4/4 bx cores was 63(16-91)%, 5(1-65)%, 4(0-30)% and 26(0-63)% respectively, suggesting significant subclonal diversity within a single lesion. ATMs were identitified in 8/13 pts. 4/13 pts (31%) had no ATM across all 4 cores. 3 pts received therapy with inhibitors targeting ATMs. A pt with AKT1_E17K ATM received an AKT inhibitor with 21% tumour shrinkage and PFS 6.1 mths. 2 NSCLC pts harbouring an EGFR_T790M ATM were treated with an EGFRT790M specific TKI. 1 withdrew due to toxicity after 2mths and another had PFS > 16.5 mths. Tumour mutational burden (TMB) was consistent across multiple bx from each lesion. A NSCLC pt with the highest TMB received a checkpoint inhibitor with ongoing > 4 mths stable disease. Conclusions: Utilizing a single pass radiologically guided techniqueto obtainmultiple bx is feasible, safe and informative. This allows reconstruction of a tumour’s subclonal genomic architecture, providing insights into mutational heterogeneity and help guide therapy.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35  (15_suppl) , 2550
Whole exome sequencing (WES) of multiple spatially distinct biopsies from single metastatic lesions to evaluate tumour heterogeneity and identify actionable truncal mutations (ATMs) in patients (pts) with advanced solid malignancies using a radiologically-guided single-pass percutaneous technique.
2550 Background: Genomic profiling of single core biopsies (bx) are confounded intratumoral heterogeneity, resulting in sampling bias. We explored the use of a novel technique to obtain multiple bx from single metastatic lesion in pts to evaluate heterogeneity and identify therapeutic ATM. Methods: 15 pts (5 NSCLC; 3 ovarian; 2 colon, 2 uterine and 1 breast, cervix and HCC) with biopsiable lesions were identified. Using a single pass radiologically guided percutaneous bx technique, we obtained multiple spatially distinct core bx samples from a single metastatic lesion. Each bx underwent DNA extraction and WES using the NextSeq500. Results: Median of 4 core bx were obtained from each lesion. Complication rate utilizing this technique was 0%. 2 pts were omitted from analysis due to poor quality DNA with 13 pts successfully sequenced. In 1 pt, only 2 of 4 cores were successfully sequenced. The median amounts of total and non-synonymous variants were 137 (27-1286) and 66 (10-649) respectively. The median (range) filtered variants detected in 1/4, 2/4, 3/4, and 4/4 bx cores was 63(16-91)%, 5(1-65)%, 4(0-30)% and 26(0-63)% respectively, suggesting significant subclonal diversity within a single lesion. ATMs were identitified in 8/13 pts. 4/13 pts (31%) had no ATM across all 4 cores. 3 pts received therapy with inhibitors targeting ATMs. A pt with AKT1_E17K ATM received an AKT inhibitor with 21% tumour shrinkage and PFS 6.1 mths. 2 NSCLC pts harbouring an EGFR_T790M ATM were treated with an EGFRT790M specific TKI. 1 withdrew due to toxicity after 2mths and another had PFS > 16.5 mths. Tumour mutational burden (TMB) was consistent across multiple bx from each lesion. A NSCLC pt with the highest TMB received a checkpoint inhibitor with ongoing > 4 mths stable disease. Conclusions: Utilizing a single pass radiologically guided techniqueto obtainmultiple bx is feasible, safe and informative. This allows reconstruction of a tumour’s subclonal genomic architecture, providing insights into mutational heterogeneity and help guide therapy.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35  (15_suppl) , 1512
Multi-gene panel testing of patients with multiple primary malignancies suspected with hereditary cancer syndrome.
1512 Background: Developing multiple primary cancers is an indicator of underlying hereditary cancer predisposition, but there is a paucity of data regarding the characteristics and clinical genetic testing outcome of these patients. Methods: We compared cancer index patients with 1 vs > 1 primary malignancy who underwent evaluation and clinical testing with multi-gene panels comprising up to 49 genes in a cancer genetics clinic in a tertiary cancer centre in Asia from 1998-2016. Results: Among 1191 cancer index patients, 960 (80.6%), 205 (17.2%), and 26 (2.2%) respectively had 1, 2, and ≥3 primary malignancies. Among patients with > 1 primary cancers (n = 231), the most common cancer pairs were breast-breast (35.4%), breast-ovary (12.1%), endometrium-ovary (8.2%), colon-colon (2.4%) and, colon-endometrium (2.4%). The mean age at diagnosis of the first, second and third cancers were 46.0 (21 to 87), 52.1 (21 to 89) and 57.7 (41 to 83) respectively. The mean duration between first and second cancers is 6.0 years (0 to 32). The most commonly suspected syndromes in patients with 1 vs > 1 primary cancer were hereditary breast and ovarian cancer 63.8% vs 53.6%, Lynch 24.8% vs 31.1%, Li-Fraumeni syndromes 1.8% vs 1.7%, and others 9.3% vs 13.4% (p = 0.03). Patients with > 1 primary cancer were more likely to have > 20% a priori risk of suspected hereditary cancer syndrome (42.8% vs. 26.5%; p < 0.001). 504/1191 (42.3%) patients underwent gene testing, including 394/960 (41.0%) and 110/231 (47.6%) patients with 1 vs > 1 cancer. Deleterious mutations were more likely to be identified in patients with > 1 vs 1 cancer (34.5% vs. 25.8%; p = 0.073), with causative genes being BRCA1 38.5%, BRCA2 17.9%, MLH1/MSH2/MSH6 20.5%, TP53 7.7%, and others (ATM [n = 2], MUTYH, APC, PALB2, RAD51 [n = 1 each]) for patients with > 1 cancer. VUS rates were 31.7% vs.31.8% in patients with 1 vs > 1 cancer, and were identified in genes including BRIP1, CHEK2, PALLD, POLE, PTEN, STK11, SMARCA4, and VHL. Conclusions: Patients with > 1 primary cancer comprised one-fifth of cancer index patients evaluated at a cancer genetics clinic, and were more likely to be found with deleterious mutations than patients with only 1 cancer on multi-gene panel testing.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35  (15_suppl) , 1512
Multi-gene panel testing of patients with multiple primary malignancies suspected with hereditary cancer syndrome.
1512 Background: Developing multiple primary cancers is an indicator of underlying hereditary cancer predisposition, but there is a paucity of data regarding the characteristics and clinical genetic testing outcome of these patients. Methods: We compared cancer index patients with 1 vs > 1 primary malignancy who underwent evaluation and clinical testing with multi-gene panels comprising up to 49 genes in a cancer genetics clinic in a tertiary cancer centre in Asia from 1998-2016. Results: Among 1191 cancer index patients, 960 (80.6%), 205 (17.2%), and 26 (2.2%) respectively had 1, 2, and ≥3 primary malignancies. Among patients with > 1 primary cancers (n = 231), the most common cancer pairs were breast-breast (35.4%), breast-ovary (12.1%), endometrium-ovary (8.2%), colon-colon (2.4%) and, colon-endometrium (2.4%). The mean age at diagnosis of the first, second and third cancers were 46.0 (21 to 87), 52.1 (21 to 89) and 57.7 (41 to 83) respectively. The mean duration between first and second cancers is 6.0 years (0 to 32). The most commonly suspected syndromes in patients with 1 vs > 1 primary cancer were hereditary breast and ovarian cancer 63.8% vs 53.6%, Lynch 24.8% vs 31.1%, Li-Fraumeni syndromes 1.8% vs 1.7%, and others 9.3% vs 13.4% (p = 0.03). Patients with > 1 primary cancer were more likely to have > 20% a priori risk of suspected hereditary cancer syndrome (42.8% vs. 26.5%; p < 0.001). 504/1191 (42.3%) patients underwent gene testing, including 394/960 (41.0%) and 110/231 (47.6%) patients with 1 vs > 1 cancer. Deleterious mutations were more likely to be identified in patients with > 1 vs 1 cancer (34.5% vs. 25.8%; p = 0.073), with causative genes being BRCA1 38.5%, BRCA2 17.9%, MLH1/MSH2/MSH6 20.5%, TP53 7.7%, and others (ATM [n = 2], MUTYH, APC, PALB2, RAD51 [n = 1 each]) for patients with > 1 cancer. VUS rates were 31.7% vs.31.8% in patients with 1 vs > 1 cancer, and were identified in genes including BRIP1, CHEK2, PALLD, POLE, PTEN, STK11, SMARCA4, and VHL. Conclusions: Patients with > 1 primary cancer comprised one-fifth of cancer index patients evaluated at a cancer genetics clinic, and were more likely to be found with deleterious mutations than patients with only 1 cancer on multi-gene panel testing.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34  (15_suppl) , 6034
Randomised study of 2 low doses of sunitinib to modulate tumor microvasculature prior to chemotherapy in nasopharyngeal carcinoma (NPC).
6034 Background: NPC is chemo- and radiosensitive but relapse rate is high and progression free survival (PFS) short for stage 4 disease. Almost all NPCs overexpress VEGF that promotes immature vasculature and poor tumor perfusion. We conducted a randomised phase 2 study of 2 low doses of sunitinib to promote maturity of tumor microvasculature prior to standard cisplatin-gemcitabine therapy in stage 4 NPC patients with the primary objectives to determine safety, tolerability and response rate (RR), and secondary objectives to determine PFS and effects on microvasculature. Methods: Eligible patients were randomised to receive sunitinib 12.5mg (ARM A) or 25mg (ARM B) daily for 7 days prior to each 3 weekly cycle of D1 cisplatin 75mg/m2 + D1, D8 gemcitabine 1000mg/m2, for 3 cycles followed by concurrent chemoradiotherapy in stage 4A/B (locally advanced) patients, and for 6 cycles in stage 4C (metastatic) patients. Enumeration of endothelial cell (CD34 antibody) and pericyte (SMA antibody) counts at 200x magnification by immunohistochemistry was performed by a blinded pathologist on tumor biopsies at baseline and cycle 1 day 7 sunitinib treatment to evaluate vascular normalization. Results: 33 patients were recruited (15 Arm A; 18 Arm B). The overall RR to induction chemotherapy was 82% (27/33) with 3 complete responses; 13/15 Arm A and 14/18 Arm B; 2 were non evaluable. At a median follow up of 23 months in stage 4A/B patients, 7/26 (27%) patients had progressed; median PFS was 9 months for stage 4C. G3/4 neutropenia without fever and thrombocytopenia without bleeding occurred in 67% and 40% in both Arms, respectively; resulting in dose delay of a week in 47% patients in Arm A and 50% in Arm B. Sunitinib alone induced early rise in plasma EBV DNA titre in 14/17 patients with detectable titres. 3/4 patients with detectable EBV DNA after induction chemotherapy relapsed within 12 months. Increase in vascular maturation reflected by increased SMA/CD34 score was seen in 75% of patients after 1 week of sunitinib in both arms. Conclusions: Sunitinib prior to chemotherapy is tolerable and active in stage 4 NPC, and induces early evidence of microvascular maturation, warranting further clinical studies. Clinical trial information: NCT01309633.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34  (15_suppl) , 6034
Randomised study of 2 low doses of sunitinib to modulate tumor microvasculature prior to chemotherapy in nasopharyngeal carcinoma (NPC).
6034 Background: NPC is chemo- and radiosensitive but relapse rate is high and progression free survival (PFS) short for stage 4 disease. Almost all NPCs overexpress VEGF that promotes immature vasculature and poor tumor perfusion. We conducted a randomised phase 2 study of 2 low doses of sunitinib to promote maturity of tumor microvasculature prior to standard cisplatin-gemcitabine therapy in stage 4 NPC patients with the primary objectives to determine safety, tolerability and response rate (RR), and secondary objectives to determine PFS and effects on microvasculature. Methods: Eligible patients were randomised to receive sunitinib 12.5mg (ARM A) or 25mg (ARM B) daily for 7 days prior to each 3 weekly cycle of D1 cisplatin 75mg/m2 + D1, D8 gemcitabine 1000mg/m2, for 3 cycles followed by concurrent chemoradiotherapy in stage 4A/B (locally advanced) patients, and for 6 cycles in stage 4C (metastatic) patients. Enumeration of endothelial cell (CD34 antibody) and pericyte (SMA antibody) counts at 200x magnification by immunohistochemistry was performed by a blinded pathologist on tumor biopsies at baseline and cycle 1 day 7 sunitinib treatment to evaluate vascular normalization. Results: 33 patients were recruited (15 Arm A; 18 Arm B). The overall RR to induction chemotherapy was 82% (27/33) with 3 complete responses; 13/15 Arm A and 14/18 Arm B; 2 were non evaluable. At a median follow up of 23 months in stage 4A/B patients, 7/26 (27%) patients had progressed; median PFS was 9 months for stage 4C. G3/4 neutropenia without fever and thrombocytopenia without bleeding occurred in 67% and 40% in both Arms, respectively; resulting in dose delay of a week in 47% patients in Arm A and 50% in Arm B. Sunitinib alone induced early rise in plasma EBV DNA titre in 14/17 patients with detectable titres. 3/4 patients with detectable EBV DNA after induction chemotherapy relapsed within 12 months. Increase in vascular maturation reflected by increased SMA/CD34 score was seen in 75% of patients after 1 week of sunitinib in both arms. Conclusions: Sunitinib prior to chemotherapy is tolerable and active in stage 4 NPC, and induces early evidence of microvascular maturation, warranting further clinical studies. Clinical trial information: NCT01309633.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34  (15_suppl) , e14124
A phase II randomized study of docetaxel +/- low-dose, short course sunitinib in advanced solid tumours.
E14124 Background: Low dose, short course anti-angiogenic agents may normalize tumor vasculature to improve drug delivery. We previously showed 12.5mg sunitinib (Su) for 7 days before neoadjuvant doxorubicin/cyclophosphamide (AC) to normalize tumor vasculature and improve response. However, Su prolonged myelosuppression and delayed AC cycles, reducing overall efficacy. In this study, we combined Su with docetaxel with an earlier neutrophil nadir to improve chemotherapy dose intensity. Methods: Patients with metastatic cancers were stratified by primary site (breast, lung and others) and randomized 1:1 to docetaxel 75mg/m23 weekly (Arm A) or with Su 12.5mg daily for 7 days before docetaxel (Arm B), up to 6 cycles. Primary endpoints were objective response (ORR; CR+PR) and clinical benefit rate (CBR; CR+PR+SD); secondary endpoints were tolerability, toxicity and progression free survival (PFS). Results: 46 patients participated, 23 in each arm. Median age was 62 (36-76 years). Arm B patients were more heavily pretreated ( ≥ 2 prior lines of palliative chemotherapy 33% vs 71% for A vs B, p = 0.127). Mean total docetaxel dose was similar (347 vs 327mg/m2for A vs B, p = 0.690) with minimal delays in each arm. Use of GCSF was more frequent in Arm B (52.9% vs 92.9%, p = 0.015), and grade 3-4 toxicities less common (52.2% vs 19%, p = 0.023), mainly neutropenia (43.5% vs 9.5%, p = 0.012). ORR was 39.1% and 30.4% (p = 0.194), while CBR was 91.3% and 65.2% in A and B respectively (p = 0.097). Median PFS was 7.4 (95% CI 5.7-9.0) vs 4.2 months (95% CI 2.3-6.2) (p = .001), and median overall survival (OS) was 12.5 months (95% CI 6.1-18.9) vs not reached (p = 0.494). After excluding non-breast/lung primaries, median PFS was 7.1 (95% CI 5.2-8.9) vs 4.4 months (95% CI 2.0-6.7) (p = 0.017); median OS was 16.7 months (95% CI 8.9-24.5) vs not reached (p = 0.474). Conclusions: Su with docetaxel is better tolerated than with AC but did not improve outcomes and appeared adverse particularly in non-breast/lung primary tumors. Clinical trial information: NCT01803503.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34  (15_suppl) , e14124
A phase II randomized study of docetaxel +/- low-dose, short course sunitinib in advanced solid tumours.
E14124 Background: Low dose, short course anti-angiogenic agents may normalize tumor vasculature to improve drug delivery. We previously showed 12.5mg sunitinib (Su) for 7 days before neoadjuvant doxorubicin/cyclophosphamide (AC) to normalize tumor vasculature and improve response. However, Su prolonged myelosuppression and delayed AC cycles, reducing overall efficacy. In this study, we combined Su with docetaxel with an earlier neutrophil nadir to improve chemotherapy dose intensity. Methods: Patients with metastatic cancers were stratified by primary site (breast, lung and others) and randomized 1:1 to docetaxel 75mg/m23 weekly (Arm A) or with Su 12.5mg daily for 7 days before docetaxel (Arm B), up to 6 cycles. Primary endpoints were objective response (ORR; CR+PR) and clinical benefit rate (CBR; CR+PR+SD); secondary endpoints were tolerability, toxicity and progression free survival (PFS). Results: 46 patients participated, 23 in each arm. Median age was 62 (36-76 years). Arm B patients were more heavily pretreated ( ≥ 2 prior lines of palliative chemotherapy 33% vs 71% for A vs B, p = 0.127). Mean total docetaxel dose was similar (347 vs 327mg/m2for A vs B, p = 0.690) with minimal delays in each arm. Use of GCSF was more frequent in Arm B (52.9% vs 92.9%, p = 0.015), and grade 3-4 toxicities less common (52.2% vs 19%, p = 0.023), mainly neutropenia (43.5% vs 9.5%, p = 0.012). ORR was 39.1% and 30.4% (p = 0.194), while CBR was 91.3% and 65.2% in A and B respectively (p = 0.097). Median PFS was 7.4 (95% CI 5.7-9.0) vs 4.2 months (95% CI 2.3-6.2) (p = .001), and median overall survival (OS) was 12.5 months (95% CI 6.1-18.9) vs not reached (p = 0.494). After excluding non-breast/lung primaries, median PFS was 7.1 (95% CI 5.2-8.9) vs 4.4 months (95% CI 2.0-6.7) (p = 0.017); median OS was 16.7 months (95% CI 8.9-24.5) vs not reached (p = 0.474). Conclusions: Su with docetaxel is better tolerated than with AC but did not improve outcomes and appeared adverse particularly in non-breast/lung primary tumors. Clinical trial information: NCT01803503.
- 1 October 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25, v53-v54
Exome Sequencing and Snp Array Reveal Epigenome Modifier Defects in Nasopharyngeal Carcinoma
Background: Nasopharyngeal carcinoma (NPC) is a type of head and neck carcinoma that develops from the lateral wall of the nasopharynx. It has a specific high incidence in south china, Hong Kong and Singapore with a poorly understood molecular basis. Methods: Whole exome sequencing(WES) and genome-wide SCNV was performed on 56 matched tumor and germline DNA to identify somatic mutations and copy number variations in NPC patients. Functional experiments were performed including knocking down and overexpression of candidate gene in NPC cells, western blots, Soft Agar colony assay, mice tumor exnograft and short time drug treatment proliferation assay. Results: A total of 1,577 nonsilent somatic mutations were discovered by WES and validated by Sanger sequencing. SCNV analysis identified recurrent copy number changes affecting P16, ARID1A and other known cancer genes. Epigenome modification proteins were observed to be frequently mutated in NPC (75%). Patients with epigenome defect showed an increase in mutation burden as well as poor overall survival. Among these mutated epigenome modifiers, ARID1A showed the most frequent alterations (19.6%). Depletion of ARID1A in NPC cells with shRNA led to a significant increase in migration, colony formation and in vivo tumor exnograft growth. On the other hand, overexpression of ARID1A showed opposite biological effect. The observations that epigenome modifiers frequently mutated in NPC suggested that HDAC inhibitors might be a novel therapeutic solution for NPC. Three inhibitors (SAHA panobinostat and belinostat) all showed potent anti-tumor effects on NPC cell lines as determined by MTT assays. Conclusions: By next generation sequencing and SNP arrays, we identified common alterations affecting epigenome modifiers in NPC and that the chromatin remodeling protein ARID1A as a novel tumor suppressor in NPC. In addition, our pre-clinical results suggested that HDAC inhibitors might be a candidate therapeutic agent for NPC treatment.
- 1 October 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25, v53-v54
Exome Sequencing and Snp Array Reveal Epigenome Modifier Defects in Nasopharyngeal Carcinoma
Background: Nasopharyngeal carcinoma (NPC) is a type of head and neck carcinoma that develops from the lateral wall of the nasopharynx. It has a specific high incidence in south china, Hong Kong and Singapore with a poorly understood molecular basis. Methods: Whole exome sequencing(WES) and genome-wide SCNV was performed on 56 matched tumor and germline DNA to identify somatic mutations and copy number variations in NPC patients. Functional experiments were performed including knocking down and overexpression of candidate gene in NPC cells, western blots, Soft Agar colony assay, mice tumor exnograft and short time drug treatment proliferation assay. Results: A total of 1,577 nonsilent somatic mutations were discovered by WES and validated by Sanger sequencing. SCNV analysis identified recurrent copy number changes affecting P16, ARID1A and other known cancer genes. Epigenome modification proteins were observed to be frequently mutated in NPC (75%). Patients with epigenome defect showed an increase in mutation burden as well as poor overall survival. Among these mutated epigenome modifiers, ARID1A showed the most frequent alterations (19.6%). Depletion of ARID1A in NPC cells with shRNA led to a significant increase in migration, colony formation and in vivo tumor exnograft growth. On the other hand, overexpression of ARID1A showed opposite biological effect. The observations that epigenome modifiers frequently mutated in NPC suggested that HDAC inhibitors might be a novel therapeutic solution for NPC. Three inhibitors (SAHA panobinostat and belinostat) all showed potent anti-tumor effects on NPC cell lines as determined by MTT assays. Conclusions: By next generation sequencing and SNP arrays, we identified common alterations affecting epigenome modifiers in NPC and that the chromatin remodeling protein ARID1A as a novel tumor suppressor in NPC. In addition, our pre-clinical results suggested that HDAC inhibitors might be a candidate therapeutic agent for NPC treatment.
- Open Access
- 24 January 2013
- Published by IntechOpen
Serial Changes in Expression of Proteins in Response to Neoadjuvant Chemotherapy in Breast Cancer
Serial Changes in Expression of Proteins in Response to Neoadjuvant Chemotherapy in Breast Cancer | InTechOpen, Published on: 2013-01-24. Authors: Daniel Chan and Soo-Chin Lee
- 24 January 2013
- Published by IntechOpen
Open AccessSerial Changes in Expression of Proteins in Response to Neoadjuvant Chemotherapy in Breast Cancer
Serial Changes in Expression of Proteins in Response to Neoadjuvant Chemotherapy in Breast Cancer | InTechOpen, Published on: 2013-01-24. Authors: Daniel Chan and Soo-Chin Lee
- 8 October 2011
- Vol. 8  (5) , 255-9
Gemcitabine and platinum pathway pharmacogenetics in Asian breast cancer patients.
Gemcitabine/carboplatin is efficacious in breast cancer but results in significant hematologic toxicities. We employed a multi-gene approach to identify variants to predict its toxicities. Twenty-six gemcitabine and platinum-based DNA repair pathway polymorphisms were correlated with gemcitabine pharmacokinetics, hematologic toxicities, response and survival in 41 Asian breast cancer patients receiving gemcitabine/carboplatin. The combined effects of solute carrier family (SLC)28A1+1528C>T and thymidylate synthetase (TYMS)+1494del6 significantly influenced hematologic toxicities: 89% of patients who possessed either SLC28A1+1528TT or TYMS+1494ins6/ins6 (n=9) developed grade 4 thrombocytopenia, versus 14% with neither genotype (n=29; p<0.001). In concordance, all patients who possessed either genotype developed grade 3/4 neutropenia, compared to 38% with neither genotype (p=0.001). None of the other genetic variants analyzed correlated with drug pharmacokinetics and pharmacodynamics. Approximately one-quarter of our Asian cohort carried SLC28A1+1528TT or TYMS+1494ins6/ins6, which are associated with increased myelotoxicity from gemcitabine/carboplatin. This has potential utility in treatment selection and genotype-based dosing strategies.
- 8 October 2011
- Vol. 8  (5) , 255-9
Gemcitabine and platinum pathway pharmacogenetics in Asian breast cancer patients.
Gemcitabine/carboplatin is efficacious in breast cancer but results in significant hematologic toxicities. We employed a multi-gene approach to identify variants to predict its toxicities. Twenty-six gemcitabine and platinum-based DNA repair pathway polymorphisms were correlated with gemcitabine pharmacokinetics, hematologic toxicities, response and survival in 41 Asian breast cancer patients receiving gemcitabine/carboplatin. The combined effects of solute carrier family (SLC)28A1+1528C>T and thymidylate synthetase (TYMS)+1494del6 significantly influenced hematologic toxicities: 89% of patients who possessed either SLC28A1+1528TT or TYMS+1494ins6/ins6 (n=9) developed grade 4 thrombocytopenia, versus 14% with neither genotype (n=29; p<0.001). In concordance, all patients who possessed either genotype developed grade 3/4 neutropenia, compared to 38% with neither genotype (p=0.001). None of the other genetic variants analyzed correlated with drug pharmacokinetics and pharmacodynamics. Approximately one-quarter of our Asian cohort carried SLC28A1+1528TT or TYMS+1494ins6/ins6, which are associated with increased myelotoxicity from gemcitabine/carboplatin. This has potential utility in treatment selection and genotype-based dosing strategies.
- 15 August 2011
- Published by Academy of Medicine, Singapore in Annals of the Academy of Medicine, Singapore
- Vol. 40  (8) , 348-349
Pharmacogenetics for Oncology Practice
- 15 August 2011
- Published by Academy of Medicine, Singapore in Annals of the Academy of Medicine, Singapore
- Vol. 40  (8) , 348-349
Pharmacogenetics for Oncology Practice
- 15 January 2011
- Published by Academy of Medicine, Singapore in Annals of the Academy of Medicine, Singapore
- Vol. 40  (1) , 36-42
Non-directive Genetic Counselling – Respect for Autonomy or Unprofessional Practice?
Historically, genetic counselling was developed in the West and in the field of neonatal medicine, and a non-directive approach has been its central ethos since the 1950s to 60s. In today's changing world, the question of whether non-directive genetic counselling with its emphasis on patient autonomy may in some occasions be perceived as unprofessional practice. Through these 4 case studies in cancer genetic counselling, we seek to highlight the conundrums, dilemmas and various other considerations of patients and their families faced during the genetic counselling process. We also address the pitfalls of a 'one-size fi ts all' approach of non-directive counselling and how we could best practice cancer genetic counselling in the Singapore context, taking into consideration respect for patient autonomy and healthcare professionalism.
- 15 January 2011
- Published by Academy of Medicine, Singapore in Annals of the Academy of Medicine, Singapore
- Vol. 40  (1) , 36-42
Non-directive Genetic Counselling – Respect for Autonomy or Unprofessional Practice?
Historically, genetic counselling was developed in the West and in the field of neonatal medicine, and a non-directive approach has been its central ethos since the 1950s to 60s. In today's changing world, the question of whether non-directive genetic counselling with its emphasis on patient autonomy may in some occasions be perceived as unprofessional practice. Through these 4 case studies in cancer genetic counselling, we seek to highlight the conundrums, dilemmas and various other considerations of patients and their families faced during the genetic counselling process. We also address the pitfalls of a 'one-size fi ts all' approach of non-directive counselling and how we could best practice cancer genetic counselling in the Singapore context, taking into consideration respect for patient autonomy and healthcare professionalism.
- 1 November 2009
- Published by Wolters Kluwer Health in Pharmacogenetics and Genomics
- Vol. 19  (11) , 833-842
Post-treatment tumor gene expression signatures are more predictive of treatment outcomes than baseline signatures in breast cancer
Tumor gene expression signatures have been used to classify, prognosticate, and predict chemotherapy sensitivity in breast cancer, although almost all efforts have been focused on the unchallenged baseline tumor. Most cancer patients receive systemic therapy, and exposure to drug may modify the tumor's short-term and long-term outcomes. Drug-induced tumor gene signatures may thus be more predictive of treatment outcomes than the unperturbed tumor gene signatures. Using a set of 47 breast cancer patients, we obtained paired prechemotherapy and postchemotherapy tumor biopsies and developed gene panels of baseline tumor (T1), postchemotherapy tumor (T2), and chemotherapy-induced relative change signatures (TΔ) to predict pathological response and progression-free survival (PFS). The signatures were validated in two independent test sets with paired prechemotherapy and postchemotherapy tumor samples, comprising of 18–20 patients each. T2 and TΔ were superior to T1 signatures in predicting for PFS (area under the curve of receiver operating characteristic 0.770 and 0.660 vs. 0.530) and pathological response (area under the curve of receiver operating characteristic 0.631 and 0.462 vs. 0.446) in the validation sets. In multivariate analysis for PFS with other clinical predictors, T2, but not T1, signatures remained as significant independent predictors. Postchemotherapy tumor gene signatures outperformed baseline signatures and clinical predictors in predicting for pathological response and PFS, independent of clinical and pathological response to chemotherapy. Drug-induced tumor gene signatures may be more informative than unchallenged signatures in predicting treatment outcomes. These findings challenge the current practice of relying only on the baseline tumor to predict outcome, which overlooks the contributions of therapeutic interventions.
- 1 November 2009
- Published by Wolters Kluwer Health in Pharmacogenetics and Genomics
- Vol. 19  (11) , 833-842
Post-treatment tumor gene expression signatures are more predictive of treatment outcomes than baseline signatures in breast cancer
Tumor gene expression signatures have been used to classify, prognosticate, and predict chemotherapy sensitivity in breast cancer, although almost all efforts have been focused on the unchallenged baseline tumor. Most cancer patients receive systemic therapy, and exposure to drug may modify the tumor's short-term and long-term outcomes. Drug-induced tumor gene signatures may thus be more predictive of treatment outcomes than the unperturbed tumor gene signatures. Using a set of 47 breast cancer patients, we obtained paired prechemotherapy and postchemotherapy tumor biopsies and developed gene panels of baseline tumor (T1), postchemotherapy tumor (T2), and chemotherapy-induced relative change signatures (TΔ) to predict pathological response and progression-free survival (PFS). The signatures were validated in two independent test sets with paired prechemotherapy and postchemotherapy tumor samples, comprising of 18–20 patients each. T2 and TΔ were superior to T1 signatures in predicting for PFS (area under the curve of receiver operating characteristic 0.770 and 0.660 vs. 0.530) and pathological response (area under the curve of receiver operating characteristic 0.631 and 0.462 vs. 0.446) in the validation sets. In multivariate analysis for PFS with other clinical predictors, T2, but not T1, signatures remained as significant independent predictors. Postchemotherapy tumor gene signatures outperformed baseline signatures and clinical predictors in predicting for pathological response and PFS, independent of clinical and pathological response to chemotherapy. Drug-induced tumor gene signatures may be more informative than unchallenged signatures in predicting treatment outcomes. These findings challenge the current practice of relying only on the baseline tumor to predict outcome, which overlooks the contributions of therapeutic interventions.